ClinicalTrials.gg
Active, not recruitingNCT06557785Updated Jan 14, 2026

A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV

A Phase 1 interventional study of CH505M5 N197D mRNA-gp160 and CH505 TF mRNA-gp160 in HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Active, not recruiting at 7 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
53
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,034 studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID) — 10 open to participants now, 15 under way, 1 of them phase 3. HIV Infections · National Institute of Allergy and Infectious Diseases (NIAID).

Enrollment
468th of 883
53 · median 59
Started
2024
with 5 others
Phase 1
365 of 1,034
4 open now
Primary completion
2027-03
later than 4 of 12 live
Registered
1,027th of 1,034
by date

Among the 1,034 studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 468th largest by enrollment of the 883 interventional ones that give a count, is one of 6 that started in 2024, is one of 365 in phase 1, reaches primary completion later than 4 of the 12 other live ones, and was the 1,027th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

10 of the 1,034 studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,034 studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID), or all of them as a file.
02

Study summary

This is a multicenter, open-label, non-randomized, dose escalation, first-in-human (FIH) trial to evaluate the safety and immunogenicity of CH505M5 N197D mRNA-gp160 and CH505 TF mRNA-gp160. Both products are mRNA encapsulated in lipid nanoparticles (LNPs) (subsequently referred to as mRNA-LNPs). The primary hypotheses are:

  1. the CH505M5 N197D mRNA-gp160 will expand CH235-like B cell precursors,
  2. the CH505 TF mRNA-gp160 will boost CH235-like bnAb B cell precursors to acquire more functional mutations needed for broadly neutralizing antibody (bnAb) development, and
  3. these mRNA-LNPs will be safe and well tolerated among individuals living without HIV.
03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Demonstrates an understanding of the study and is able and willing to complete the process.
  2. 18 to 55 years old, inclusive, on day of enrollment.
  3. Available for clinic follow-up through the last clinic visit and willing to undergo FNA of an axillary lymph node and undergo leukapheresis.
  4. Agrees not to enroll in another study of an agent during participation in the trial. If a potential participant is already enrolled in another clinical trial, approvals from the other trial sponsor and the HVTN 312 Protocol Safety Review Team (PSRT) are required prior to enrollment into HVTN 312.
  5. In good general health according to the clinical judgment of the site investigator.
  6. Physical examination and laboratory results without findings that would interfere with assessment of safety or reactogenicity in the clinical judgement of the site investigator.
  7. For US sites: Agrees to discuss their potential for acquisition and agrees to prevention counseling.
  8. For non-US sites: Assessed by clinical staff as having a low likelihood of acquiring HIV per guidelines, agrees to discuss their potential for HIV acquisition, agrees to prevention counseling, and agrees to avoid behaviors associated with a higher likelihood of acquiring HIV through the final study visit. "Low likelihood" may include persons stably taking pre-exposure prophylaxis (PrEP) as prescribed.
  9. (Hgb):

    • ≥ 11.0 g/dL for AFAB volunteers
    • ≥ 13.0 g/dL for cisgender AMAB volunteers or for volunteers who have been on masculinizing hormone therapy for more than 6 consecutive months
    • ≥ 12.0 g/dL for AMAB volunteers who have been on feminizing hormone therapy for more than 6 consecutive months
    • For volunteers who have been on gender-affirming hormone therapy for less than 6 consecutive months, determine Hgb eligibility based on their sex assigned at birth.
  10. White blood cell (WBC) count = 2,500 to 12,000/mm3 (WBC over 12,000/mm3 is not exclusionary if further evaluation shows general good health and if PSRT approval is granted).
  11. = 125,000 to 550,000/mm3.
  12. (ALT) \< 2.5 x upper limit of institutional reference range.
  13. Serum creatinine ≤ 1.1 x (ULN) based on the institutional normal range.
  14. Total measured or corrected serum calcium level of > 8.5 mg/dL. Corrected serum calcium should only be used if the total serum calcium is below the lower limit of normal.
  15. Systolic blood pressure of 90 to \< 140 mmHg and diastolic blood pressure of 50 to \< 90 mmHg at screening visit. The average blood pressure between the screening visit and the enrollment visit must be below 140 mmHg systolic and 90 mmHg diastolic. A single measurement ≥ 160 systolic mmHg or 100 mmHg diastolic during the current study evaluation is exclusionary.
  16. Negative HIV test results by one of the following options:

    For US volunteers:

    • US Food and Drug Administration (FDA)-approved enzyme immunoassay (EIA)
    • Chemiluminescent microparticle immunoassay (CMIA)
    • Two negative results on HIV rapid tests (one of which must be FDA-approved CMIA)

    For non-US volunteers:

    • A negative European Conformity (CE)-marked enzyme immunoassay (EIA)
    • A chemiluminescent microparticle immunoassay (CMIA)
    • A negative result on 2 HIV rapid tests (one of these rapid tests must be CE-marked)
  17. Negative for anti- virus (HCV) Abs (anti-HCV) or negative HCV nucleic acid test (NAT) if anti-HCV Abs are detected.
  18. Negative for surface Ag.
  19. For AFAB or intersex at birth volunteers who are capable of becoming pregnant (hereafter referred to as "persons of pregnancy potential"):

    • Must agree to use effective means of from at least 21 days prior to enrollment through 8 weeks after their last scheduled vaccination timepoint.
    • Must have a negative beta human chorionic gonadotropin (β-HCG) pregnancy test (urine or serum) on the day of enrollment.
  20. AFAB or intersex at birth volunteers must agree to not seek pregnancy through alternative methods, such as oocyte retrieval, artificial insemination, or in vitro fertilization from at least 21 days prior to enrollment through 8 weeks after their last scheduled vaccination timepoint.

Exclusion criteria

Exclusion Criteria:

  1. Volunteer who is breastfeeding/chestfeeding or pregnant.
  2. (BMI) ≥ 40. Enrollment of individuals with BMI ≥ 40, whom the site investigator assesses are in good health, may be considered by PSRT approval.
  3. Diabetes mellitus (DM). Type 2 DM controlled with diet alone (and confirmed by HgbA1c ≤ 8% within the last 6 months) or a history of isolated gestational diabetes are not exclusionary. Enrollment of individuals with Type 2 DM that is well controlled on hypoglycemic agent(s) may be considered by the PSRT on a case-by-case basis, provided that the HgbA1c is ≤ 8% within the last 6 months (sites may draw these at screening).
  4. Previous or current recipient of an vaccine or HIV mAb (previous placebo/control recipients are not excluded).
  5. Receipt of non-HIV investigational vaccine(s) received within the last 1 year. Exceptions include vaccines that have subsequently undergone licensure or Emergency Use Authorization (EUA) by the FDA or World Health Organization (WHO) Emergency Use Listing (EUL), or if outside the US, by the national Regulatory Authority (RA) authorizing this clinical trial.
  6. Congenital or acquired immunodeficiency, including systemic medication use likely to impair immune response to vaccine in the opinion of the site investigator, such as use, ≥ prednisone 10 mg/day within 3 months prior to enrollment.
  7. Blood products or immunoglobulin within 16 weeks prior to enrollment; receipt of immunoglobulin within 16 weeks prior to enrollment requires PSRT approval.
  8. Receipt of any of the following within 4 weeks prior to enrollment:

    • Live replicating vaccine
    • Any mRNA-based vaccine with FDA licensure, FDA EUA, or WHO EUL
    • ACAM2000 vaccine > 28 days prior with a vaccination scab still present.
  9. Receipt of any vaccine that is not covered in exclusion criterion #8 within 14 days prior to enrollment. Please note this includes replication-incompetent vaccines such as the Jynneos vaccine for the prevention of mpox disease.
  10. History of myocarditis and/or pericarditis.
  11. Initiation of Ag-based immunotherapy for allergies within the previous year (stable immunotherapy is not exclusionary); inclusion of participants who initiated immunotherapy within the previous year requires PSRT approval.
  12. Receipt of investigational research agents with a half-life of 7 or fewer days within 4 weeks prior to enrollment. If a potential participant has received investigational agents with a half-life of more than 7 days (or unknown half-life) within the past year, PSRT approval is required for enrollment.
  13. History of serious reaction (eg, , anaphylaxis) to any mRNA vaccine, including Comirnaty® (Pfizer) and Spikevax® (Moderna), or to any drug administered systemically as a polyethylene glycol containing LNP, including doxorubicin (Doxil, Caelyx, ThermoDox), cisplatin (Lipoplatin) and irinotecan (Onivyde).
  14. Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema.
  15. Urticaria within the last year unless it was caused by a known, definable, and avoidable trigger (ie, urticaria by a known, definable and avoidable trigger would not be exclusionary).
  16. History of chronic urticaria or urticaria previously associated with immunization.
  17. Bleeding disorder diagnosed by a clinician that would make study procedures a .
  18. History of seizure(s) within the past 3 years. Also exclude if volunteer has used medications in order to prevent or treat seizure(s) at any time within the past 3 years.
  19. Asplenia or functional asplenia.
  20. Active duty and reserve US military personnel.
  21. Any other chronic or condition that, in the clinical judgment of the investigator, would jeopardize the safety or rights of the study participant, hinder their ability to participate in the study, or affect their immune responses to study products. Such conditions include but not limited to: clinically significant forms of substance use or alcohol use disorder(s), serious psychiatric disorders, any suicide attempt within the past 1 year (if between 1 and 2 years, consult PSRT for approval), or cancer that, in the clinical judgement of the site investigator, has potential for recurrence (excluding basal cell carcinoma).
  22. Asthma is excluded if the participant has ANY of the following:

    • Required either oral or parenteral corticosteroids for an exacerbation 2 or more times within the past year; OR
    • Needed emergency care, urgent care, hospitalization, or intubation for an acute asthma exacerbation within the past year (eg, would NOT exclude individuals with asthma who meet all other criteria but sought urgent/emergent care solely for asthma medication refills or coexisting conditions unrelated to asthma); OR
    • Uses a short-acting rescue inhaler more than 2 days per week for acute asthma symptoms (ie, not for preventive treatment prior to athletic activity); OR
    • Uses medium- to high-dose inhaled corticosteroids (> 250 mcg fluticasone or therapeutic equivalent per day), whether in single-therapy or dual-therapy inhalers (ie, with a long-acting beta agonist [LABA]); OR
    • Uses more than 1 medication for maintenance therapy daily. Inclusion of anyone on a stable dose of more than 1 medication for maintenance therapy daily for greater than 2 years requires PSRT approval.
  23. A participant with a history of a potential immune-mediated medical condition (PIMMC), either active or remote. Not exclusionary: 1) Remote history of Bell's palsy (> 2 years ago) not associated with other neurologic symptoms and 2) mild psoriasis or other mild, uncomplicated, localized or dermatologic condition that does not require ongoing systemic treatment.
  24. History of allergy to local anesthetic (Novocain, Lidocaine).
  25. Investigator concern for difficulty with venous access based on clinical history and physical examination. For example, persons with a history of IV drug use or substantial difficulty with previous blood draws.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Group 1 (25 mcg)

    25 mcg of CH505M5 N197D mRNA-gp160, to be administered as a split dose intramuscularly at weeks 0, 8, and 16. Followed by: 25 mcg of CH505 TF mRNA-gp160, to be administered as a split dose intramuscularly at week 24.

    Biological: CH505M5 N197D mRNA-gp160 · Biological: CH505 TF mRNA-gp160

  • Experimental
    Group 2 (50 mcg)

    50 mcg of CH505M5 N197D mRNA-gp160, to be administered as a split dose intramuscularly at weeks 0, 8, and 16. Followed by: 50 mcg of CH505 TF mRNA-gp160, to be administered as a split dose intramuscularly at week 24.

    Biological: CH505M5 N197D mRNA-gp160 · Biological: CH505 TF mRNA-gp160

  • Experimental
    Group 3 (100 mcg)

    100 mcg of CH505M5 N197D mRNA-gp160, to be administered as a split dose intramuscularly at weeks 0, 8, and 16. Followed by: 100 mcg of CH505 TF mRNA-gp160, to be administered as a split dose intramuscularly at week 24.

    Biological: CH505M5 N197D mRNA-gp160 · Biological: CH505 TF mRNA-gp160

  • Experimental
    Group 4 (150 mcg)

    150 mcg of CH505M5 N197D mRNA-gp160, to be administered as a split dose intramuscularly at weeks 0, 8, and 16. Followed by: 150 mcg CH505 TF mRNA-gp160, to be administered as a split dose intramuscularly at week 24.

    Biological: CH505M5 N197D mRNA-gp160 · Biological: CH505 TF mRNA-gp160

Interventions

  • BiologicalCH505M5 N197D mRNA-gp160

    To be administered intramuscularly as a split dose

  • BiologicalCH505Studies of CH505CH505 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    To be administered intramuscularly as a split dose

06

What researchers measure

Primary outcomes

  1. Frequency of local reactogenicity signs and symptoms after receipt of any study vaccine

    Time frame: Day 15, 71, 127 and 183 (14 days following receipt of any study vaccine)

  2. Frequency of systemic reactogenicity signs and symptoms after receipt of any study vaccine

    Time frame: Day 15, 71, 127 and 183 (14 days following receipt of any study vaccine)

  3. Number of serious adverse events (SAEs) leading to early participant withdrawal or permanent discontinuation

    Time frame: 20 months

  4. Number of medically attended adverse events (MAAEs) leading to early participant withdrawal or permanent discontinuation

    Time frame: 20 months

  5. Number of adverse events of special interest (AESIs) leading to early participant withdrawal or permanent discontinuation

    Time frame: 20 months

  6. Number of adverse events (AEs) leading to early participant withdrawal or permanent discontinuation

    Time frame: 20 months

  7. Response rate of CD4-bs and CH505M5-specific IgG+ B cells as assessed by flow cytometry

    Time frame: Day 127 and 183 (2 weeks after the third and fourth vaccinations)

  8. Response rate of serum Ab neutralization of vaccine-matched tier 2 HIV-1 strains, as measured by TZM-bl assay

    Time frame: Day 127 and 183 (2 weeks after the third and fourth vaccinations)

  9. Magnitude of serum Ab neutralization of vaccine-matched tier 2 HIV-1 strains, as measured by TZM-bl assay

    Time frame: Day 127 and 183 (2 weeks after the third and fourth vaccinations)

  10. Response rate of differential serum antibody neutralization of precursor detection virus and corresponding epitope KO virus, as measured by the TZM-bl assay

    Time frame: Day 127 and 183 (2 weeks after the third and fourth vaccinations)

  11. Magnitude of differential serum antibody neutralization of precursor detection virus and corresponding epitope KO virus, as measured by the TZM-bl assay

    Time frame: Day 127 and 183 (2 weeks after the third and fourth vaccinations)

Secondary outcomes

  1. Response rate of serum IgG binding antibodies to autologous and heterologous HIV Env stabilized trimers, as assessed by binding antibody multiplex assay (BAMA)

    Time frame: Day 127 and 183 (2 weeks after the third and fourth vaccinations)

  2. Magnitude of serum IgG binding antibodies to autologous and heterologous HIV Env stabilized trimers, as assessed by BAMA

    Time frame: Day 127 and 183 (2 weeks after the third and fourth vaccinations)

  3. Response rate of serum Ab neutralization of heterologous HIV-1 strains as measured by TZM-bl assay

    Time frame: Day 127 and 183 (2 weeks after the third and fourth vaccinations)

  4. Magnitude of serum Ab neutralization of heterologous HIV-1 strains as measured by TZM-bl assay

    Time frame: Day 127 and 183 (2 weeks after the third and fourth vaccinations)

  5. Frequency of CD4-bs specific sequences, as measured by BCR single cell sequencing of CD4-bs and CH505M5-specific IgG+ B cells

    Time frame: 20 months

  6. Epitope specific response rates as measured by electron microscopy-based polyclonal epitope mapping (EMPEM)

    Time frame: Day 183 (2 weeks after the fourth vaccination)

  7. Response rate of serum IgG binding Abs to Env Trimers and neutralizing epitopes as assessed by BAMA

    Time frame: Day 337 (24 weeks after the fourth vaccination)

  8. Magnitude of serum IgG binding Abs to Env Trimers and neutralizing epitopes as assessed by BAMA

    Time frame: Day 337 (24 weeks after the fourth vaccination)

  9. Response rate of serum Ab neutralization of autologous, heterologous and precursor HIV-1 strains as measured by TZM-bl assay

    Time frame: Day 337 (24 weeks after the fourth vaccination)

  10. Magnitude of serum Ab neutralization of autologous, heterologous and precursor HIV-1 strains as measured by TZM-bl assay

    Time frame: Day 337 (24 weeks after the fourth vaccination)

  11. Response rate of CD4-bs and CH505M5-specific IgG+ B cells as measured by flow cytometry

    Time frame: Day 337 (24 weeks after the fourth vaccination)

07

Study locations

7 sites
  • Beth Israel Deaconess Medical Center (Site ID: 32077)
    Boston, Massachusetts 02215, United States
  • Columbia P&S (Site ID: 30329)
    New York, New York 10032, United States
  • New York Blood Center (Site ID: 31801)
    New York, New York 10065, United States
  • Penn Prevention (Site ID: 30310)
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh (Site ID: 1001)
    Pittsburgh, Pennsylvania 15213, United States
  • Seattle Vaccine and Prevention (Site ID: 30331)
    Seattle, Washington 98104, United States
  • Vaccine Trial Centre, Mahidol University CRS (Site ID: 32021)
    Bangkok, Ratchathewi 10400, Thailand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Mar 2027, 27 months after the start.

Of 91 non-industry phase 1 interventional studies under HIV Infections, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's planned 27 months is close to that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2024
First posted
Aug 16, 2024
StartActual
Nov 25, 2024
Primary completionEst.
Mar 9, 2027
CompletionEst.
Mar 9, 2027
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06557785
Collaborators
National Institutes of Health (NIH), Department of Health and Human Services
Responsible party
Sponsor
First posted
Aug 16, 2024
Start date
Nov 25, 2024
Primary completion
Mar 9, 2027 (estimated)
Completion
Mar 9, 2027 (estimated)
Last update
Jan 14, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CH505

Start the discussion